45 results about "FSH - Follicle-stimulating hormone" patented technology

The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.

The invention discloses a culture method for high-efficiency human follicle stimulating hormone expression CHO cells and belongs to the technical field of bio-pharmaceuticals. According to the culture method, seed cells are prepared into cell suspension, and subculture is performed after resuspension through a serum-free basal culture medium to obtain seed suspension; the obtained seed suspension is inoculated into a bioreactor to be cultured, the serum-free basal culture medium is fed at regular intervals in the culture process, growth situations of the cells are monitored, glucose solution is supplemented, and the cells are harvested after culture. According to the method, the serum-free basal culture medium is used throughout the process, culture in a fermentation tank is performed after reviving and amplification through bottle shaking, the process flow is simple, the cell culture density is high and can be as high as 4*107/mL , the cell survival rate reaches more than 98%, maintaining time under high density and a high survival rate is long, the yield of end products can reach 40mg/L, and the method is applicable to industrial production.

The invention provides recombinant forms of piscine follicle-stimulating hormone (FSH) with characteristic intramolecular disulfide bonds and modified glycosylation patterns in the β-subunit that enhance the stability and metabolic activity of the hormone. Also provided are recombinant materials to produce the FSH β and glycoprotein α-subunits singly or in combination to obtain complete heterodimeric hormone of regulated glycosylation pattern. The piscine FSH agonists of the invention are therapeutically useful to expedite the onset of puberty in captive fish and to alleviate reproductive dysfunctions in fish. Likewise, the piscine FSH antagonists of the invention will be therapeutically useful to halt gonadal development, thereby contributing to body weight gain of the fish,

The present invention provides methods of producing biologically active recombinant bFSH and methods of increasing reproduction in mammals, particularly bovine, using recombinant bFSH. Also provided are methods of producing single chain recombinant bFSH. The recombinant bFSH of the present invention increases superovulation, embryo development, and reproductive efficiency in cattle and other ungulates.

The invention provides high-specific-activity recombinant human follicle stimulating hormone and a preparation method thereof. In addition, the invention also provides a method for preparing an intermediate used in the method, gene, vector and cells.

Methods are provided for the establishment and maintenance in long term culture of hormone secreting cells. Cells are derived from tumorous or non-tumorous animal or human tissues, including ovary, endometrium, trophoblast, pituitary, thyroid, and pancreas. The cells secrete into the culture medium hormones such as estrogens, progestins, follicle-stimulating hormone, luteinizing hormone, human chorionic gonadotrophin, thyroxin, glucagon, and insulin, depending on the tissue of origin of individual cell cultures. Contact with an appropriate secretogogue causes the cells to respond with increased hormone secretion. For instance, ovarian follicular cells respond to follicle-stimulating hormone with increased estrogen and progesterone secretion. Pancreatic cells respond to elevated glucose with increased insulin secretion. The cells proliferate in in vitro for up to one year or longer, during which time they retain their hormone-secretion profile. The cells may be frozen for storage, and retain their hormone-secretion profile after thawing. The cell cultures are useful for the production of human hormones, for the bio-assay of drugs such as therapeutic gonadotrophin, for the testing of drug efficacy and design, and for toxicity testing of drugs and chemicals. The cells may also be implanted in an individual to replace deficient hormone secretion. For instance, insulin secreting pancreatic cells may be implanted in a diabetic individual as an adjunct or replacement therapy for exogenously administered insulin.

Novel benzamide derivatives of formula (I)

wherein W¹, W², R¹ to R¹⁰ and X have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.

The present invention relates to recombinant human follicle-stimulating hormone and a preparation method and a drug application thereof. The recombinant human follicle-stimulating hormone is rhFSH heterodimer containing alpha and beta chains; for a mammalian cell CHO expression system, optimized design of coding genes is performed; and expression plasmids are constructed in a targeted manner, so that expression and correct combination of the alpha and beta chains of the hFSH in mammalian cells CHO are better facilitated. The rhFSH has the advantages of simple process, high target product yield, high purity, high in vivo activity, convenience for intermediate process control, easiness for large-scale production and the like.

A system and a method for assessing the ovarian reserve function of a subject. The system for assessing a subject's ovarian reserve function comprises: a data acquisition module configured to acquire data of the subject's age, anti-Müllerian hormone (AMH) level, follicle stimulating hormone (FSH) level, and antral follicle count (AFC); and an ovarian reserve function calculation module configured to calculate the above-mentioned information acquired in the data acquisition module, so as to work out the subject's probability of poor ovarian response (p). Further, the population is divided into four groups according to the interaction relationship between the predicted probability of poor ovarian response and the dose of ovulation stimulants, so as to divide the population with similar ovarian responses into one group.

The invention relates to the technical field of biological detection methods, in particular to a method for determining follicle-stimulating hormone. The method comprises the following steps of: (1) manufacturing a micro-fluidic chip; (2) mixing hydrogel with a capture antibody, and curing the mixture in the micro-fluidic chip; (3) adding the micro-fluidic chip into a detection sample and incubating the sample, so that FSH in the detection sample is combined with the capture antibody; (4) adding a dyed detection antibody and incubating the sample, so that the dyed detection antibody is combined with the FSH-antibody conjugate to emit fluorescence; and (5) photographing the detected hydrogel, analyzing the fluorescence intensity of the photographed picture, and calculating the content of follicle-stimulating hormone in the detected sample. According to the method for determining the follicle-stimulating hormone, a novel detection mode is generated through combination of a microfluidic technology and ELISA, the required sample amount is small, and one-step, rapid and quantitative detection of the FSH content in the detection sample is realized.

The invention discloses an ovulation detection test strip. The ovulation detection test strip comprises a PVC bottom plate, a sample pad, a gold label pad, a nitrocellulose film and a water absorption pad, wherein the nitrocellulose film is provided with a detection line T1, a detection line T2 and a quality control line, the detection line T1 is coated with a mouse anti-human beta LH monoclonal antibody 1A4, the detection line T2 is coated with a cotinine antigen, and the quality control line is coated with a goat anti-chicken IgY polyclonal antibody; and a colloidal gold mouse anti-human beta LH monoclonal antibody 6B8 conjugate, a colloidal gold chicken IgY antibody conjugate and a colloidal gold cotinine monoclonal antibody conjugate are cured on the gold label pad. The test strip is high in detection sensitivity and good in specificity, abnormal interpretation results caused by crossing of LH with follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH) can be avoided, detection results are more accurate, and monitoring of the smoking metabolite cotinine in urine is combined. The invention further discloses an ovulation detection method, the steps are simple, and the test result is accurate.

A method of inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor. A method for augmenting ovulation in an ovulating female suffering from unexplained infertility or another type of ovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor early in one or more menstrual cycles. A method of substantially reducing dosage levels of follicle stimulating hormone (FSH) for administration to a female undergoing infertility treatment which comprises administering a combination of two or more daily doses of at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH). A method of increasing response to a follicle stimulating hormone from a female who is a poor responder to follicle stimulation, which comprises administering a combination of two or more daily doses or at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH). Also disclosed are related pharmaceutical preparations and uses.

The invention discloses a recombinant human follicle stimulating hormone and a preparation method thereof. The preparation method comprises the following steps: jointly transfecting a constructed expression vector containing an FSHalpha subunit and an expression vector containing an FSHbeta subunit into Chinese hamster ovary cells, screening out stably expressed cell strains, and purifying and culturing the cell strains to obtain a culture solution, thereby obtaining the recombinant human follicle stimulating hormone, wherein the C-terminus of the FSHbeta subunit is connected with CTP. According to the preparation method of the recombinant human follicle stimulating hormone, hFSHalpha and hFSHbeta sequences comprising introns are cloned from human embryonic kidney 293 cell genomes respectively, CTP sequences are connected to the terminus of the beta subunit in a primer extension mode to obtain hFSHbeta-CTP, then the two subunit sequences are transfected to CHO-S cells, rhFSH-CTP is obtained through expression, the half-life period of the rhFSH-CTP obtained by expression in vivo is longer, the final half-life period is 2-3 times that of recombinant FSH, and the biological activity is higher.

The present invention relates to a method for purifying follicle stimulating hormone with high yield and high purity.

A method of improving sexual function in premenopausal women, who have low Female Sexual Function Index (FSFI) baseline of less than or equal to 25.7. The method includes providing information to premenopausal women to provide input for calculating the FSFI score and, if the score is low, providing dehydroepiandrosterone (DHEA) supplementation to be taken in 25 mg dosages daily once, twice, thrice or four times over a period of time of four to six weeks. By the end of the period of time, the FSFI baselines of the premenopausal women improves by at least seven percent, serum androgen levels of the premenopausal women increase and follicle-stimulating hormone (FSH) levels of the premenopausal women decrease.

The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.